In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Swiss Authorities Say Sparklers Most Likely Caused New Year’s Fire An official said the sparklers were attached to bottles of champagne held too close to the ceiling. Forty people died and more than ...
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. It operates through the Active Ingredient and Biopharmaceutical segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback